InvestorsHub Logo
Followers 826
Posts 119567
Boards Moderated 14
Alias Born 09/05/2002

Re: None

Tuesday, 04/02/2019 9:42:23 AM

Tuesday, April 02, 2019 9:42:23 AM

Post# of 209
Abicipar pegol (a/k/a DARPin) shows 8.9% ocular inflammation in open-label study with new manufacturing process—lower than the 15% rate in prior phase-3 trials, but still too high to be competitive (IMO):

https://finance.yahoo.com/news/allergan-molecular-partners-announce-topline-110000485.html

AGN, by its own admission, was aiming for an inflammation rate in the low-to-mid single digits.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”